News Update

Tech Firm Launches Medical Cannabis User Data App, Lands Partnership

News Update
  ()
This 'patient-care solution" is designed to help retailers make product recommendations. read more >
News Update

Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease

News Update
  ()
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates. read more >

Texas Heart Takes to the CoreoGraft

Contributed Opinion
  ()
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. read more >

FDA Approves Biopharma's Drug with $1.75 Billion Peak Sales Potential

Research Report
  ()
An H.C. Wainwright & Co. report covered the greenlighting of two therapeutics developed by this firm, whose stock, according to the analyst, has more than fivebagger return potential. read more >

This Biotech Is 'Harnessing the Microbiome's Therapeutic Potential'

Research Report
  ()
A LifeSci Capital report presented a handful of key points about the firm. read more >
News Update

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements

News Update
  ()
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. read more >

DURECT Receives Return on Schizophrenia Drug Approval

  ()
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. read more >

Surgical Robotics Developer Demonstrates Technology at Medical Conference

Research Report
  ()
A Ladenburg Thalmann report relayed how this Massachusetts company participated at the Transcatheter Cardiovascular Therapeutics annual meeting through a live transmission—the first ever—of a remote interventional procedure using the CorPath GRX system. read more >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters

Research Report
  ()
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. read more >

Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal

Research Report
  ()
An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer. read more >
Expert Investing Ideas

"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


"PMN is seeking to forge partnerships with big pharmas."

–André Uddin, Mackie Research Capital


Institutional Capital and Cannabis Conference

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program

Research Report
  ()
A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer. read more >
News Update

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm

News Update
  ()
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. read more >
News Update

Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock

News Update
  ()
This is the second large shipment to the Philippine distributor. read more >

This Company Has Better Numbers than Tilray at 1/25th the Price

Contributed Opinion
  ()
Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer. read more >
Institutional Capital and Cannabis Conference